http://hl7.org/fhir/uv/ebm/Citation/267246
type: Citation
node role: treeRoot
id:
  v: 267246
meta:
  version id:
    v: 12
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Citation 267246 version: 12; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. identifier: FEvIR Object Identifier/267246, https://pubmed.ncbi.nlm.nih.gov/11232013, <a href="http://terminology.hl7.org/7.0.1/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt #xD;#xA;#xD;#xA;This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: #xD;#xA;#xD;#xA;Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.#xD;#xA;#xD;#xA;This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.46 version: 1.0.0-ballot3 title: 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. status: Active date: 2026-01-13 11:03:07+0000 author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: HL7 International / Clinical Decision Support contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base jurisdiction: World copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2001-04-12 lastRevie…
contained: Practitioner
  id:
    v: contributor0
  name:
    family:
      v: Lebovitz
    given:
      v: H E
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Dole
    given:
      v: J F
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Patwardhan
    given:
      v: R
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Rappaport
    given:
      v: E B
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: Freed
    given:
      v: M I
contained: Organization
  id:
    v: contributor5
  name:
    v: Rosiglitazone Clinical Trials Study Group
contained: ArtifactAssessment
  id:
    v: meshHeading0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: Citation
      l: Citation
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000368
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000369
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D001786
    free to share:
      v: true
    component:
      classifier:
        coding: Q000032
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D003924
    free to share:
      v: true
    component:
      classifier:
        coding: Q000097
    component:
      classifier:
        coding: Q000188
    component:
      classifier:
        coding: Q000503
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D004311
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D005260
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D006801
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D007004
    free to share:
      v: true
    component:
      classifier:
        coding: Q000009
    component:
      classifier:
        coding: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D007515
    free to share:
      v: true
    component:
      classifier:
        coding: Q000187
    component:
      classifier:
        coding: Q000503
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D008297
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D008875
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: http://id.nlm.nih.gov/mesh/D000077154
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D016037
    free to share:
      v: true

v: mesh-heading

v: MeSH heading

v: D000368

v: Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000369

v: Aged, 80 and over

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D001786

v: Blood Glucose

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000032
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000032
display:
  v: analysis

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D003924

v: Diabetes Mellitus, Type 2

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000097
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000097
display:
  v: blood

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

Q000188
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000188
display:
  v: drug therapy

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: qualifier

Q000503
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000503
display:
  v: physiopathology

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D004311

v: Double-Blind Method

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D005260

v: Female

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D006801

v: Humans

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D007004

v: Hypoglycemic Agents

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000009
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000009
display:
  v: adverse effects

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

Q000627
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D007515

v: Islets of Langerhans

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000187
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000187
display:
  v: drug effects

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

Q000503
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000503
display:
  v: physiopathology

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D008297

v: Male

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008875

v: Middle Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000077154

v: Rosiglitazone

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D016037

v: Single-Blind Method

v: false

type:
  text:
    v: qualifier
classifier:
  text:
    v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D013844
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D013844
    display:
      v: Thiazoles
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000009
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000009
      display:
        v: adverse effects
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000627
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000627
      display:
        v: therapeutic use
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

v: C49488

v: Yes

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D045162
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D045162
    display:
      v: Thiazolidinediones
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is Major topic

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 267246
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 11232013

system:
  v: urn:ietf:rfc:3986
  l: 3986
value:
  v: urn:oid:2.16.840.1.113883.4.642.40.44.15.46

v: 1.0.0-ballot3

v: 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

v: active

v: 2026-01-13T11:03:07+00:00

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: HL7 International / Clinical Decision Support

name:
  v: HL7 International / Clinical Decision Support
telecom:
  system:
    v: url
  value:
    v: http://www.hl7.org/Special/committees/dss

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

coding:
  system:
    v: http://unstats.un.org/unsd/methods/m49/m49.htm
    l: m49.htm
  code:
    v: 001
  display:
    v: World

v: 2001-04-12

v: 2018-11-30

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: pubmed-publication-status-ppublish
  display:
    v: PubMed PublicationStatus of ppublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2001-03-07T10:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2001-04-17T10:01:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2001-03-07T10:00:00.000Z

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 11232013
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1210/jcem.86.1.7157
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  text:
    v: Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions.
relates to:
  type:
    v: correction-in
  classifier:
    coding: D016425
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016425
      display:
        v: Published Erratum
      user selected:
        v: false
  citation:
    v: J Clin Endocrinol Metab 2001 Apr;86(4):1659
relates to:
  type:
    v: correction-in
  classifier:
    coding: D016425
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016425
      display:
        v: Published Erratum
      user selected:
        v: false
  citation:
    v: J Clin Endocrinol Metab. 2002 Feb;2(1):iv.
publication form:
  published in:
    identifier:
      system:
        v: https://portal.issn.org
        l: portal.issn.org
      value:
        v: 0021-972X
    identifier:
      system:
        v: https://www.issn.org/services/online-services/access-to-the-ltwa/
        l: access-to-the-ltwa
      value:
        v: J Clin Endocrinol Metab
    identifier:
      system:
        v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
        l: the-issn-l-for-publications-on-multiple-media
      value:
        v: 0021-972X
    identifier:
      system:
        v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
        l: contructitleabbre.html
      value:
        v: J Clin Endocrinol Metab
    identifier:
      system:
        v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
        l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      value:
        v: 0375362
    title:
      v: The Journal of clinical endocrinology and metabolism
    publisher location:
      v: United States
  cited medium:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-medium
        l: cited-medium
      code:
        v: print
      display:
        v: Print
  volume:
    v: 86
  issue:
    v: 1
  article date:
    v: 2001-01
  page string:
    v: 280-8
web location:
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
        l: artifact-url-classifier
      code:
        v: abstract
      display:
        v: Abstract
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/11232013/
    l: https://pubmed.ncbi.nlm.nih.gov/11232013/
classification:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: publishing-model
      display:
        v: Publishing Model
      user selected:
        v: false
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: Print
      display:
        v: Print
      user selected:
        v: false
classification:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: chemical
      display:
        v: Chemical
      user selected:
        v: false
  classifier:
    coding: D001786
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D001786
      display:
        v: Blood Glucose
      user selected:
        v: false
  classifier:
    coding: D007004
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D007004
      display:
        v: Hypoglycemic Agents
      user selected:
        v: false
  classifier:
    coding: D013844
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D013844
      display:
        v: Thiazoles
      user selected:
        v: false

v: D020492

v: Periodical

system:
  v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn
  l: issn
code:
  v: Print
display:
  v: Print

v: Print ISSN Type

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: ISOAbbreviation

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: ISSN Linking

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: Medline Title Abbreviation

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: NLM Unique ID

coding: D045162
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D045162
  display:
    v: Thiazolidinediones
  user selected:
    v: false

coding:
  system:
    v: https://www.cas.org/support/documentation/chemical-substances
    l: chemical-substances
  code:
    v: 05V02F2KDG
  user selected:
    v: false
coding: http://id.nlm.nih.gov/mesh/D000077154
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D000077154
  display:
    v: Rosiglitazone
  user selected:
    v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier:
  coding: D016430
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016430
    display:
      v: Clinical Trial
    user selected:
      v: false
classifier:
  coding: D016428
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
classifier:
  coding: D016448
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016448
    display:
      v: Multicenter Study
    user selected:
      v: false
classifier:
  coding: D016449
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016449
    display:
      v: Randomized Controlled Trial
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Lebovitz HE
  forename initials:
    v: HE
  affiliation:
    display:
      v: Department of Medicine, State University of New York, Brooklyn, New York 11203, USA. hlebovitz@attglobal.net
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Dole JF
  forename initials:
    v: JF
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Patwardhan R
  forename initials:
    v: R
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Rappaport EB
  forename initials:
    v: EB
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Freed MI
  forename initials:
    v: MI
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Organization
      l: Organization
    display:
      v: Rosiglitazone Clinical Trials Study Group